A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Nicolino Ruperto; Pierre Quartier; Nico Wulffraat; Patricia Woo; Angelo Ravelli; Richard Mouy; Brigitte Bader-Meunier; Sebastiaan J. Vastert; Emanuele Noseda; Daniele D'Ambrosio; Jean Lecot; Abhijit Chakraborty; Alberto Martini; Andrea Chioato;

doi:10.1002/art.33342

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Arthritis & Rheumatism ◽

10.1002/art.33342 ◽

2012 ◽

Vol 64 (2) ◽

pp. 557-567 ◽

Cited By ~ 133

Author(s):

Nicolino Ruperto ◽

Pierre Quartier ◽

Nico Wulffraat ◽

Patricia Woo ◽

Angelo Ravelli ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Ii ◽

Systemic Juvenile Idiopathic Arthritis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Reporting a phase II, open-label study assessing the safety and efficacy of MS1819-SD, a recombinant lipase, for the treatment of exocrine pancreatic insufficiency

HPB ◽

10.1016/j.hpb.2019.03.317 ◽

2019 ◽

Vol 21 ◽

pp. S173-S174

Author(s):

L. Lebreton ◽

G. Smith ◽

P. Jais ◽

M. Schue ◽

T. Spoor

Keyword(s):

Phase Ii ◽

Pancreatic Insufficiency ◽

Exocrine Pancreatic Insufficiency ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Recombinant Lipase

Download Full-text

A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps9080 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS9080-TPS9080 ◽

Cited By ~ 2

Author(s):

Kim Allyson Margolin ◽

Hussein Abdul-Hassan Tawbi ◽

Marc S. Ernstoff ◽

F. Stephen Hodi ◽

David F. McDermott ◽

...

Keyword(s):

Phase Ii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

The Brain

Download Full-text

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

Neuro-Oncology ◽

10.1093/neuonc/noq072 ◽

2010 ◽

Vol 12 (10) ◽

pp. 1061-1070 ◽

Cited By ~ 75

Author(s):

W. K. A. Yung ◽

J. J. Vredenburgh ◽

T. F. Cloughesy ◽

P. Nghiemphu ◽

B. Klencke ◽

...

Keyword(s):

Phase Ii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

First Relapse

Download Full-text

A phase II, single-dose, open-label study to investigate the safety and efficacy of OTL38 injection for intraoperative imaging of folate receptor-alpha positive ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.03.081 ◽

2017 ◽

Vol 145 ◽

pp. 29-30

Author(s):

L.M. Randall ◽

R.M. Wenham ◽

P.S. Low ◽

S.C. Dowdy ◽

J.L. Tanyi

Keyword(s):

Ovarian Cancer ◽

Single Dose ◽

Phase Ii ◽

Folate Receptor ◽

Intraoperative Imaging ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Receptor Alpha

Download Full-text

127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.03.141 ◽

2021 ◽

Vol 32 ◽

pp. S76

Author(s):

K.D. Miller ◽

L.A. Emens ◽

S.M. Tolaney ◽

S.A. Hurvitz ◽

E. Hamilton ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Case Medical Research ◽

10.31525/ct1-nct03977792 ◽

2019 ◽

Author(s):

Keyword(s):

Herpes Labialis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Recurrent Herpes ◽

Cold Sores

Download Full-text

An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

Case Medical Research ◽

10.31525/ct1-nct04180774 ◽

2019 ◽

Author(s):

Keyword(s):

Malignant Melanoma ◽

Tumor Cell ◽

Renal Cell ◽

Cell Cancer ◽

Locally Advanced ◽

Metastatic Malignant Melanoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Faculty of 1000 evaluation for Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717998895.793474496 ◽

2013 ◽

Author(s):

David Kushner

Keyword(s):

Cervical Cancer ◽

Phase Ii ◽

Survival Data ◽

Open Label ◽

Recurrent Cervical Cancer ◽

Open Label Study ◽

Label Study

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725336183.793540487 ◽

2017 ◽

Author(s):

Lori Ann Birder

Keyword(s):

Overactive Bladder ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Post Marketing

Download Full-text

Safety and Efficacy of Oral Human Parathyroid Hormone (1‐34) in Hypoparathyroidism: An Open‐Label Study

Journal of Bone and Mineral Research ◽

10.1002/jbmr.4274 ◽

2021 ◽

Author(s):

Sofia Ish‐Shalom ◽

Yoseph Caraco ◽

Nariman Saba Khazen ◽

Michal Gershinsky ◽

Auryan Szalat ◽

...

Keyword(s):

Parathyroid Hormone ◽

Human Parathyroid Hormone ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text